HAEMATO AG, Berlin (ISIN: DE0006190705), published the annual report 2019 on May 11, 2020 as previously announced in the financial calendar.

HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 197.8 million (previous year: EUR 274.1 million), an operating profit (EBIT) of EUR -19 thousand (previous year: EUR 6.6 million) and an annual profit of EUR -1.17 million (previous year: EUR 6.3 million).

The annual report is available for download on our corporate website at https://haemato.ag/en/investor-relations/publications.

As one of the leading providers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the primary healthcare market. The specialization in medicines for the treatment of chronic diseases and for individual therapies leads us to expect a potential for growth in the future due to demographic development.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 22,867,154
Listed class of shares: bearer ordinary shares
ISIN: DE000619070
WKN: 619070
Stock exchange code: HAE